Financial Summary for the Fiscal Year Ending December 2025 [IFRS] (Consolidated)

Overview of Financial Results

For the fiscal year ending December 2025, consolidated revenue was JPY 496.8 billion (0.3% YoY increase), core operating income was JPY 103.1 billion (8.0% YoY increase), profit before tax was JPY 87.2 billion (4.5% YoY increase), and net income attributable to owners of parent was JPY 67.0 billion (12.0% YoY increase). Revenue increased despite the business restructuring in the APAC region and drug price revisions in Japan, driven by growth in global strategic products centered in North America and EMEA and increased technology revenues. Core operating income rose due to higher overseas sales and technology income, alongside decreases in selling, general and administrative expenses and research and development expenses.

Earnings Guidance for Fiscal Year Ending December 2026

The consolidated earnings forecast for the fiscal year ending December 2026 projects revenue of JPY 520.0 billion (4.7% YoY increase), core operating income of JPY 100.0 billion (9.0% YoY decrease), profit before tax of JPY 95.0 billion (8.9% YoY increase), and net income of JPY 75.0 billion (11.9% YoY increase). Although revenue is expected to be affected by drug price revisions in Japan and business transfers in EMEA, growth in global strategic products primarily in North America and EMEA and increased technology income are anticipated. Core operating income is forecasted to benefit from gross profit growth but challenged by higher research and development expenses and increased costs related to reacquiring development rights for locatlimab.